Interestingly, it has been noted that the anticancer effects of NAMPTis in pancreatic cancer are not influenced by either SIRT1 or PARP1, indicating that the impact of NAMPT on PARP1 or sirtuins may vary depending on the type of cancer. This evidence concerns the gene PARP1 and familial pancreatic carcinoma.